U.S. markets close in 6 hours 2 minutes

(ARTH)

. Currency in USD
Add to watchlist
0.08910.0000 (0.00%)
As of 3:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0891
Open0.0999
BidN/A x N/A
AskN/A x N/A
Day's Range0.0891 - 0.0891
52 Week Range0.0881 - 0.2270
Volume1,097,358
Avg. VolumeN/A
Market Cap21.092M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021
    GlobeNewswire

    Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021

    FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Mike Abrams, are scheduled to present via webcast, which will be available on-demand as of 4:15 PM ET, Thursday, Jun. 10, 2021. You m

  • Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS)
    GlobeNewswire

    Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS)

    Honors for Highest Scoring Poster Abstract in Case Series/Study Category Confirms Commercialization Opportunities for AC5® Advanced Wound SystemFRAMINGHAM, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, presents two clinical case reports supporting the broad potential of AC5® Advanced Wound System in chronic and non-healing wounds at the 2021 Symposium on Advanced Wound Care (SAWC) Spring this week. Both abstracts are available as Poster Presentations, and one abstract qualified for Podium Presentation in the Rapid Fire Symposium and earned a ribbon designation in the Poster Hall as the 2021 Highest Scoring Poster Abstract in the “Case Series/Study” category. Terrence W. Norchi, MD, President and CEO of Arch, said, “We are honored by the designation awarded by the expert panel of SAWC judges. This endorsement supports that the observed clinical benefits provided by AC5 Advanced Wound System may be a game-changer for interventional wound care, which includes both chronic and acute surgical wounds.” AC5® Advanced Wound System received marketing authorization by the US Food and Drug Administration and is now commercially available. A comparable product, AC5® Topical Hemostat, received a CE mark in Europe. Daniel C. Wadsworth, VP of Dermal Sciences, stated, “The clinical case reports presented at SAWC further confirm the effectiveness of AC5 Advanced Wound System in patients with significant comorbidities and prior failed treatments. Our growing body of clinical data provides further support for use of AC5 Advanced Wound System as first-line therapy for patients with or at risk for stalled or chronic wounds.” The following clinical case reports, which are now available online to all SAWC attendees, examine the use of the AC5® Advanced Wound System in patients with chronic and non-healing wounds: Rapid Healing of a Chronic Trophic Ulcer in a Patient with Peripheral Vascular and Autoimmune Comorbidities using a Novel Self-assembling Peptide-based Advanced DressingLaura Pfendler PT DPT, Kalpana Kamath PhD, Daniel Wadsworth, Daniel Kapp MDPoster #: CS-45 Poster Hall Ribbon Designation: 2021 Highest Scoring Poster Abstract Case Series/StudyPodium Presentation: May 11, 2021 4pm EDTConclusion: Complete healing of this recalcitrant trophic ulcer, which was unresponsive to multiple wound management regimens during the prior four years, was achieved with only three applications of AC5 in less than three weeks. The phenomenon was particularly impressive, considering the patient’s multiple vascular and autoimmune diseases, known to hinder the progression of wound healing and likely contributing to failure of prior wound-care regimens. Effective Management of a Non-healing Wound Post-Mohs Surgery using a Novel Self-assembling Peptide-based Advanced Wound DressingLaura Pfendler PT DPT, Kalpana Kamath PhD, Daniel Wadsworth, Daniel Kapp MDPoster #: CS-44Conclusion: Concomitant use of excisional debridement and treatment with AC5 markedly accelerated healing of this stalled wound, which had failed two months of standard therapy. The effect of AC5 may be attributed to the contiguous barrier it creates along the wound surface after debridement, in addition to its ability to promote cell adhesion, migration, and proliferation, which are essential for wound healing. Mr. Wadsworth added, “The significance of the clinical case report on the patient with the chronic trophic ulcer should be noted. The patient had a prior amputation that began with a non-healing wound, and the surgeon’s objective was to ensure that the current chronic wound did not lead to another amputation. Not only was that objective met, but AC5 Advanced Wound System supported the healing of the four-year-old trophic ulcer with three applications in less than three weeks.” Dr. Norchi concluded, “With the understanding that approximately 7 million people in the U.S are living with a chronic wound and that thousands of surgeons and other healthcare providers may benefit from AC5 Advanced Wound System, the commercial opportunities are significant.” About Arch Therapeutics, Inc.Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2 About the Symposium on Advanced Wound CareThe Symposium on Advanced Wound Care (SAWC) is the Official Meeting Site of the Wound Healing Society. The SAWC conference aims to connect the entire wound care team— physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians—with the foremost experts in wound care to improve patient outcomes through education. The Spring SAWC event will engage over 1,500 surgeons, wound care providers and other wound care specialists in the vital role emerging therapies play in chronic wound care and prevention. Notice Regarding Forward-Looking StatementsThis news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. _____________________1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries. Contact:ARTH Investor RelationsToll Free: +1-855-340-ARTH (2784) (US and Canada)Email: investors@archtherapeutics.com Website: www.archtherapeutics.com or Michael AbramsChief Financial OfficerArch Therapeutics, Inc.Phone: 617-431-2308Email: mabrams@archtherapeutics.com Website: www.archtherapeutics.com

  • Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer
    GlobeNewswire

    Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer

    Company Prepares for Next Stage of GrowthFRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has appointed Michael S. Abrams its Chief Financial Officer effective May 10, 2021. In alignment with the Company’s succession plan, Mr. Abrams joins Arch’s financial team today, one week before assuming the role currently held by the Company’s Chief Financial Officer, Richard Davis. Mr. Davis will remain with the Company during a Transition Period, which will end on June 30, 2021, after which he will support the Company in a consulting role through December 31, 2021. Mr. Abrams has over 25 years of experience as a Chief Financial Officer to numerous public and private companies; principal investor; investment banker; merchant banker; strategic and financial advisor; and Board member. Mr. Abrams’ capabilities span a broad range of activities with a particular expertise in the areas of operational management, complex financial engineering, financial advisory, and capital markets strategy primarily for companies in the technology and healthcare sectors. Mr. Abrams graduated with an MBA with Honors from the Booth School of Business at the University of Chicago and received his BBA with Honors from the University of Massachusetts at Amherst as a William F. Field Alumni scholar, an award given annually to the top finance student in the class. Terrence W. Norchi, M.D., Chief Executive Officer of Arch Therapeutics, said, “I am pleased to welcome Mike to our leadership team. His deep and extensive experience in leading financial operations will support our immediate and ongoing commercialization and R&D efforts and continue to position Arch as an industry leader. I am confident Mike will provide strong leadership and is an excellent addition to the organization.” “On behalf of our board of directors and all of us at the Company, I thank Rick Davis for his exceptional contributions throughout his tenure at Arch,” added Norchi. “In his seven years as CFO, Rick has been a prodigious leader, mentor and colleague, and his guidance has been instrumental to Arch’s success. I wish Rick all the best in the next chapter of his life.” Mr. Abrams commented, “I am thrilled to join Arch, a company I have long admired and one that has innovative, game-changing medical device technologies. Arch has unique strengths and tremendous opportunities worldwide with its current and future products. I look forward to working with the team to execute on the Company’s priorities, accelerate growth and enhance value for shareholders and stakeholders.” Rick Davis, Arch Chief Financial Officer said, “It has been a privilege and honor to work with my colleagues at Arch. I have strived to do right by all, our shareholders, employees, suppliers and now our customers. I have the utmost confidence that Terry, Mike and the rest of the team will maximize this opportunity for all stakeholders.” Terrence W. Norchi, M.D., Chief Executive Officer of Arch Therapeutics, concluded, “I again want to thank Rick on both a professional and personal basis for his care and commitment to Arch and to me. At the very same time, I look forward to working with Mike for many years to come building and expanding upon the foundation of Arch’s accomplishments and value proposition.” About Arch Therapeutics, Inc.Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2 Notice Regarding Forward-Looking StatementsThis news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries. Contact:ARTH Investor RelationsToll Free: +1-855-340-ARTH (2784) (US and Canada)Email: investors@archtherapeutics.com Website: www.archtherapeutics.com